Jupiter Endovascular Revenue and Competitors

Imagine a world where you could bring the precision and control of surgery to catheter-based therapies.\n\n\nFor decades, endovascular procedures have been constrained by the technological limitations of catheters that lose stability and control within the anatomy. We have created a new class of therapies to overcome these constraints by using Endoportal Control to mimic the precision and control of direct surgical access, while maintaining the minimally invasive profile of an endovascular intervention. Our vision is big, spanning the breadth of cardiovascular disease where we see compelling opportunities to reimagine therapies for millions of patients.\n\n\nJupiter Endovascular is a medical technology startup located in the San Francisco Bay Area, led by a team of successful medical device entrepreneurs. We have big ambitions, with a culture built on innovation, teamwork, and speed. We have raised capital from a diversified investor base, including venture capital, private equity, corporate strategic investors, and clinician angel investors.